Christopher van Dyck

Summary

Affiliation: Yale University
Country: USA

Publications

  1. pmc Memantine: efficacy and safety in mild-to-severe Alzheimer's disease
    Rajesh R Tampi
    Department of Psychiatry
    Neuropsychiatr Dis Treat 3:245-58. 2007
  2. ncbi request reprint A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil
    Christopher H van Dyck
    Department of Psychiatry, Yale University, New Haven, Connecticut 06510, USA
    Am J Geriatr Psychiatry 14:428-37. 2006
  3. ncbi request reprint Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, One Church Street, New Haven, CT 06510, USA
    J Nucl Med 46:745-51. 2005
  4. pmc Striatal dopamine transporters correlate with simple reaction time in elderly subjects
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, United States
    Neurobiol Aging 29:1237-46. 2008
  5. ncbi request reprint Understanding the latest advances in pharmacologic interventions for Alzheimer's disease
    Christopher H van Dyck
    Alzheimer s Disease Research Unit, Yale University School of Medicine, 1 Church Street, New Haven, CT 06510, USA
    CNS Spectr 9:24-8. 2004
  6. ncbi request reprint Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Am J Psychiatry 161:525-31. 2004
  7. ncbi request reprint A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease
    Christopher H van Dyck
    Yale University School of Medicine, New Haven, CT 06510, USA
    Alzheimer Dis Assoc Disord 21:136-43. 2007
  8. ncbi request reprint Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease
    C H van Dyck
    Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, Conn 06520, USA
    Arch Neurol 55:1460-6. 1998
  9. pmc Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home study
    Christopher H van Dyck
    Azheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Int Psychogeriatr 21:138-47. 2009
  10. ncbi request reprint Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, Cognitive Disorders Clinic, New Haven, CT 06510, USA
    Am J Psychiatry 159:309-12. 2002

Detail Information

Publications45

  1. pmc Memantine: efficacy and safety in mild-to-severe Alzheimer's disease
    Rajesh R Tampi
    Department of Psychiatry
    Neuropsychiatr Dis Treat 3:245-58. 2007
    ..In this article, we review the evidence for the use of memantine in patients with AD, ranging from the mild to severe stages of disease...
  2. ncbi request reprint A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil
    Christopher H van Dyck
    Department of Psychiatry, Yale University, New Haven, Connecticut 06510, USA
    Am J Geriatr Psychiatry 14:428-37. 2006
    ..The objective of this study was to examine the clinical utility of memantine for moderate-to-severe Alzheimer disease (AD) using responder analyses...
  3. ncbi request reprint Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, One Church Street, New Haven, CT 06510, USA
    J Nucl Med 46:745-51. 2005
    ..Previous investigations of the effects of the SLC6A3 polymorphism on DAT availability in smaller samples of humans have yielded divergent results...
  4. pmc Striatal dopamine transporters correlate with simple reaction time in elderly subjects
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, United States
    Neurobiol Aging 29:1237-46. 2008
    ..These results demonstrate that a loss of nigrostriatal dopaminergic function likely contributes to slowing of reaction speed with advancing age...
  5. ncbi request reprint Understanding the latest advances in pharmacologic interventions for Alzheimer's disease
    Christopher H van Dyck
    Alzheimer s Disease Research Unit, Yale University School of Medicine, 1 Church Street, New Haven, CT 06510, USA
    CNS Spectr 9:24-8. 2004
    ..The clinical efficacy and tolerability of memantine monotherapy and combination therapy in patients with AD will be presented. Finally, the role of nonpharmacologic intervention will be discussed...
  6. ncbi request reprint Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Am J Psychiatry 161:525-31. 2004
    ..In vitro studies of nonneural cells have suggested that the long allele may have higher transcriptional activity than the short allele. However, the relevance of these findings for SERT levels in the brain remains unclear...
  7. ncbi request reprint A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease
    Christopher H van Dyck
    Yale University School of Medicine, New Haven, CT 06510, USA
    Alzheimer Dis Assoc Disord 21:136-43. 2007
    ..The type and incidence of adverse events were similar in both groups...
  8. ncbi request reprint Absence of an apolipoprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease
    C H van Dyck
    Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, Conn 06520, USA
    Arch Neurol 55:1460-6. 1998
    ..However, previous research has shown minimal effect of the epsilon4 allele on regional cerebral blood flow (rCBF) and metabolism in patients with probable AD...
  9. pmc Cognitive and psychiatric effects of vitamin B12 replacement in dementia with low serum B12 levels: a nursing home study
    Christopher H van Dyck
    Azheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Int Psychogeriatr 21:138-47. 2009
    ..The aim of this study is to determine whether B12 replacement would ameliorate cognitive and psychiatric symptoms in elderly subjects with dementia and low serum B12 levels...
  10. ncbi request reprint Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, Cognitive Disorders Clinic, New Haven, CT 06510, USA
    Am J Psychiatry 159:309-12. 2002
    ..The authors examined whether patients with attention deficit hyperactivity disorder (ADHD) have altered striatal dopamine transporter levels, which may explain psychostimulant effects in this disorder...
  11. ncbi request reprint Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries
    Christopher H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Am J Geriatr Psychiatry 10:36-43. 2002
    ..These findings have implications not only for healthy aging but also for neurodegenerative disorders such as PD...
  12. ncbi request reprint Neuroimaging in Alzheimer's disease: relevance for treatment
    C H van Dyck
    Alzheimer s Disease Research Unit, CB 2041, Yale University School of Medicine, 1 Church Street, Suite 600, New Haven, CT 06510, USA
    Curr Psychiatry Rep 3:13-9. 2001
    ..Neuroimaging studies of AD patients and asymptomatic subjects who carry the apolipoprotein E e4 allele suggest that these individuals may be particularly suitable for testing candidate prevention therapies for AD...
  13. ncbi request reprint Equilibrium modeling of 5-HT(2A) receptors with [18F]deuteroaltanserin and PET: feasibility of a constant infusion paradigm
    C H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06520, USA
    Nucl Med Biol 27:715-22. 2000
    ..These results demonstrate feasibility of equilibrium imaging with [(18)F]deuteroaltanserin and suggest that it may be superior to [(18)F]altanserin as a PET radioligand...
  14. ncbi request reprint Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT
    C H van Dyck
    Department of Psychiatry, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
    Neurobiol Aging 21:497-501. 2000
    ..5% over the age range 18 to 88, or approximately 4.2% per decade. These results demonstrate reductions in the availability of central SERT binding sites with age in living human subjects...
  15. ncbi request reprint Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group
    C H van Dyck
    Department of Psychiatry, Yale University School of Medicine, New Haven, Conn 06520, USA
    Arch Gen Psychiatry 57:157-64. 2000
    ..The efficacy of extended-release physostigmine salicylate, an acetylcholinesterase inhibitor, was evaluated in 850 subjects with mild-to-moderate Alzheimer disease (AD) in a multicenter trial...
  16. ncbi request reprint Apolipoprotein E epsilon4 allele is unrelated to cognitive or functional decline in Alzheimer's disease: retrospective and prospective analysis
    Timothy Kleiman
    Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Dement Geriatr Cogn Disord 22:73-82. 2006
    ..This study aimed to determine whether ApoE epsilon4 dose is related to the progression of cognitive and functional decline in AD patients by combined retrospective and prospective analyses...
  17. doi request reprint 123I-5-IA-85380 SPECT imaging of nicotinic receptors in Alzheimer disease and mild cognitive impairment
    Effie M Mitsis
    Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, Connecticut, USA
    J Nucl Med 50:1455-63. 2009
    ..However, the status of this receptor in mild or prodromal AD has remained the subject of controversy...
  18. pmc Age-related decline in nicotinic receptor availability with [(123)I]5-IA-85380 SPECT
    Effie M Mitsis
    Yale University School of Medicine, New Haven, CT 06510, USA
    Neurobiol Aging 30:1490-7. 2009
    ..These results in living human subjects corroborate postmortem reports of decline in high affinity nicotine binding with age and may aid in elucidating the role of beta(2)-nAChRs in cognitive aging...
  19. doi request reprint Regional distribution and behavioral correlates of 5-HT(2A) receptors in Alzheimer's disease with [(18)F]deuteroaltanserin and PET
    Lekshmi Santhosh
    Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, CT 06510, USA
    Psychiatry Res 173:212-7. 2009
    ..However, in a limited AD patient sample, they fail to demonstrate a relationship between regional 5-HT(2A) binding and major behavioral symptoms...
  20. ncbi request reprint 123I-5-IA-85380 SPECT measurement of nicotinic acetylcholine receptors in human brain by the constant infusion paradigm: feasibility and reproducibility
    Julie K Staley
    Department of Psychiatry, Yale University School of Medicine, Veterans Affairs Connecticut Healthcare System, West Haven, CT 06516, USA
    J Nucl Med 46:1466-72. 2005
    ..The feasibility and reproducibility of the bolus-plus-constant-infusion paradigm for equilibrium modeling of (123)I-5-IA using SPECT in healthy nonsmokers was studied...
  21. ncbi request reprint Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers
    Julie K Staley
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06511, USA
    J Neurosci 26:8707-14. 2006
    ..Greater beta2*-nAChR availability during early abstinence may impact the ability of smokers to maintain abstinence...
  22. ncbi request reprint Increase in prefrontal cortex serotonin 2A receptors following estrogen treatment in postmenopausal women
    Akira Kugaya
    Department of Psychiatry, Yale University, New Haven, Conn 06516, USA
    Am J Psychiatry 160:1522-4. 2003
    ..This study investigated the effect of estrogen on brain serotonin 2A (5-HT(2A)) receptors in postmenopausal women and whether there was any correlation of receptor changes with cognition and mood...
  23. ncbi request reprint 123I-5-IA-85380 SPECT imaging of nicotinic acetylcholine receptor availability in nonsmokers: effects of sex and menstrual phase
    Kelly P Cosgrove
    Yale University School of Medicine, New Haven, Connecticut, USA
    J Nucl Med 48:1633-40. 2007
    ..We examined the availability of nAChR containing the beta(2) subunit in healthy men and women and the influence of menstrual phase among women...
  24. ncbi request reprint [123I]5-IA-85380 SPECT imaging of beta2-nicotinic acetylcholine receptor availability in the aging human brain
    Effie M Mitsis
    Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    Ann N Y Acad Sci 1097:168-70. 2007
    ..Preliminary results have confirmed postmortem reports of age-related decline in high-affinity nicotine binding with age and may elucidate the role of beta(2)-nAChRs in the cognitive decline associated with aging...
  25. ncbi request reprint Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors
    Akira Kugaya
    Department of Psychiatry, Yale University, New Haven, Connecticut, USA
    Biol Psychiatry 56:497-502. 2004
    ..This study used brain imaging to examine the relationship between pretreatment brain SERT availability and transporter occupancy by SSRIs with treatment response in two independent depressed populations...
  26. ncbi request reprint Striatal dopamine transporter availability with [123I]beta-CIT SPECT is unrelated to gender or menstrual cycle
    Susan E Best
    Department of Psychiatry, Yale University School of Medicine, Suite 600, One Church Street, New Haven, CT 06510, USA
    Psychopharmacology (Berl) 183:181-9. 2005
    ..The effect of gender and female menstrual cycle on human striatal dopamine transporters (DATs) was investigated with single-photon emission computed tomography (SPECT) using the ligand 2beta-carbomethoxy-3beta-(4-[(123)I]iodophenyl)tropane...
  27. ncbi request reprint Cortical gamma-aminobutyric acid type A-benzodiazepine receptors in recovery from alcohol dependence: relationship to features of alcohol dependence and cigarette smoking
    Julie K Staley
    Yale University School of Medicine, 950 Campbell Avenue, New Haven, CT 06516, USA
    Arch Gen Psychiatry 62:877-88. 2005
    ..Adaptations in gamma-aminobutyric acid type A (GABA(A))-benzodiazepine receptors contribute to the neurobiology of human alcohol dependence and withdrawal...
  28. pmc Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease
    Douglas Galasko
    From the Department of Neurosciences D G, R G T, P S A, University of California, San Diego Pfizer Global Research and Development J B, J Y M, J W K, Cambridge, MA Banner Sun Health Research Institute M N S, Sun City University of Arizona M N S, Tucson and the Department of Psychiatry C v D, Yale University, New Haven, CT
    Neurology 82:1536-42. 2014
    ..To examine safety, tolerability, and efficacy of PF-04494700, an inhibitor of the receptor for advanced glycation end products (RAGE), in mild to moderate Alzheimer disease (AD)...
  29. ncbi request reprint A functional neuropeptide Y Leu7Pro polymorphism associated with alcohol dependence in a large population sample from the United States
    Jaakko Lappalainen
    Yale University School of Medicine, Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Ave, Psychiatry 116A2, West Haven, CT 06516, USA
    Arch Gen Psychiatry 59:825-31. 2002
    ..We tested whether the Pro7 allele is associated with alcohol dependence in European Americans (EA)...
  30. pmc BDNF variants, premorbid educational attainment, and disease characteristics in Alzheimer's disease: an exploratory study
    Kristina F Zdanys
    Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, New Haven, CT 06510, USA
    J Alzheimers Dis 17:887-98. 2009
    ..The effect of the Val66Met polymorphism on premorbid educational attainment is intriguing and should be verified in a larger sample...
  31. pmc Alpha2A-adrenoceptor stimulation improves prefrontal cortical regulation of behavior through inhibition of cAMP signaling in aging animals
    Brian P Ramos
    Department of Neurobiology, Yale University School of Medicine, New Haven, Connecticut 06510, USA
    Learn Mem 13:770-6. 2006
    ..These results are consistent with alpha2A-adrenoceptor stimulation enhancing PFC working-memory function via inhibition of cAMP-mediated signaling...
  32. pmc Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence
    Huiping Zhang
    Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut 06516, USA
    Am J Med Genet B Neuropsychiatr Genet 141:387-93. 2006
    ..The negative results for AFDs, PTSD, and schizophrenia could be due to the low statistical power. Further study with larger samples is warranted...
  33. ncbi request reprint Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease
    Kristina F Zdanys
    Alzheimer s Disease Research Unit, Yale University School of Medicine, New Haven, CT 06510, USA
    Neuropsychopharmacology 32:171-9. 2007
    ..In conclusion, AD patients who carry the ApoE epsilon4 allele are at greater risk than noncarriers for developing psychotic symptoms, particularly as the severity of their dementia progresses...
  34. ncbi request reprint Volumetry of amygdala and hippocampus and memory performance in Alzheimer's disease
    Michael Basso
    Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, One Church Street, New Haven, CT 06510, USA
    Psychiatry Res 146:251-61. 2006
    ..While a substantial literature continues to justify the focus on the hippocampus in MRI studies of AD, these results suggest that the amygdala should receive similar attention, including in studies of the prodromal stages of AD...
  35. pmc Inhibition of protein kinase C signaling protects prefrontal cortex dendritic spines and cognition from the effects of chronic stress
    Avis Brennan Hains
    Department of Neurobiology, Yale University School of Medicine, 333 Cedar Street SHM C 303, New Haven, CT 06510, USA
    Proc Natl Acad Sci U S A 106:17957-62. 2009
    ....
  36. ncbi request reprint Apolipoprotein E epsilon4 is associated with atrophy of the amygdala in Alzheimer's disease
    Michael Basso
    Alzheimer s Disease Research Unit, Department of Psychiatry, Yale University School of Medicine, One Church Street, Suite 600, New Haven, CT 06510, USA
    Neurobiol Aging 27:1416-24. 2006
    ..These results suggest accelerated atrophy of the amygdala in AD in association with ApoE epsilon4 and provide further evidence for regionally specific effects of this allele...
  37. ncbi request reprint Vitamin E and donepezil for the treatment of mild cognitive impairment
    Ronald C Petersen
    Mayo Clinic College of Medicine, Rochester, Minn, USA
    N Engl J Med 352:2379-88. 2005
    ..Mild cognitive impairment is a transitional state between the cognitive changes of normal aging and early Alzheimer's disease...
  38. ncbi request reprint Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD 20892 0135, USA
    Eur J Nucl Med Mol Imaging 30:1620-9. 2003
    ..These results demonstrate the feasibility of quantifying high-affinity type nAChRs using [123I]5-I-A-85380 in humans and support the use of VT' measured by bolus studies...
  39. ncbi request reprint Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials
    Michael Grundman
    Alzheimer s Disease Cooperative Study, Department of Neurosciences, University of California San Diego, 8950 Villa La Jolla Drive, Suite 227, La Jolla, CA 92037, USA
    Arch Neurol 61:59-66. 2004
    ..The Memory Impairment Study (MIS) is a multicenter clinical trial in patients with MCI designed to evaluate whether vitamin E or donepezil is effective at delaying the time to a clinical diagnosis of AD...
  40. ncbi request reprint Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis
    Frederick A Schmitt
    Department of Neurology, University of Kentucky Medical Center, Sanders Brown Center on Aging, Lexington, KY 40536, USA
    Alzheimer Dis Assoc Disord 20:255-62. 2006
    ....
  41. pmc Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials
    Jason Karlawish
    Department of Medicine, Alzheimer s Disease Center, Leonard Davis Institute for Health Economics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, School of Medicine, PA, USA
    Am J Geriatr Psychiatry 16:568-74. 2008
    ..Among Alzheimer disease (AD) patients enrolled in a clinical trial, the authors assessed the ability of a standardized capacity assessment procedure to identify persons who are capable of giving their own informed consent...
  42. pmc High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial
    Paul S Aisen
    Department of Neurosciences, University of California, San Diego, 9500 Gilman Dr, M C 0949, La Jolla, CA 92093, USA
    JAMA 300:1774-83. 2008
    ..Prior studies of B vitamins to reduce homocysteine in AD have not had sufficient size or duration to assess their effect on cognitive decline...
  43. ncbi request reprint Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment
    Adam Fleisher
    Department of Neurosciences, University of California San Diego, La Jolla, Calif, USA
    Arch Neurol 62:953-7. 2005
    ..The presence of the apolipoprotein E epsilon4 (APOE*E4) allele has been associated with greater hippocampal atrophy in women than in men with Alzheimer disease. This relationship has not been demonstrated in MCI...
  44. ncbi request reprint NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)
    Illana Gozes
    Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 69978, Israel
    CNS Drug Rev 11:353-68. 2005
    ..NAP is poised for further clinical development targeting several indications, including Alzheimer's disease...
  45. doi request reprint The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment
    Jason Karlawish
    Department of Medicine, Alzheimer s Disease Center, Leonard Davis Institute for Health Economics, University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Am J Geriatr Psychiatry 16:240-7. 2008
    ..To examine the views of Alzheimer disease (AD) patients and their study partners on the ethics of proxy consent for clinical research...

Research Grants5

  1. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher van Dyck; Fiscal Year: 2009
    ..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..
  2. Guanfacine Treatment for Prefrontal Cognitive Dysfunction in Elderly Subjects
    Christopher H van Dyck; Fiscal Year: 2010
    ..This Pilot Clinical Trial will provide essential preliminary data for a subsequent full-scale trial of guanfacine for prefrontally-mediated cognitive dysfunction in elderly subjects. ..